Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 4
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
The next generation virus-like particle platform for the treatment of peanut allergy.
Sobczak JM, Krenger PS, Storni F, Mohsen MO, Balke I, Reseviča G, Heath MD, Carreno Velazquez TL, Kramer MF, Scott CJW, Skinner MA, Zeltiņš A, Kündig TM, Vogel M, Bachmann MF. Sobczak JM, et al. Among authors: krenger ps. Allergy. 2023 Jul;78(7):1980-1996. doi: 10.1111/all.15704. Epub 2023 Mar 29. Allergy. 2023. PMID: 36883475 Free article.
Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies.
Vogt AS, Jörg L, Martina B, Krenger PS, Chang X, Zeltins A, Vogel M, Mohsen MO, Bachmann MF. Vogt AS, et al. Among authors: krenger ps. Front Immunol. 2022 Jun 16;13:864718. doi: 10.3389/fimmu.2022.864718. eCollection 2022. Front Immunol. 2022. PMID: 35784292 Free PMC article.
BALB/c and C3H mice are both suitable as peanut allergy models.
Krenger PS, Sobczak J, Paolucci M, Kündig TM, Johansen P, Vogel M, Bachmann MF. Krenger PS, et al. Clin Exp Allergy. 2023 Dec;53(12):1310-1313. doi: 10.1111/cea.14398. Epub 2023 Oct 4. Clin Exp Allergy. 2023. PMID: 37792733 Free article. No abstract available.
A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2.
Mohsen MO, Balke I, Zinkhan S, Zeltina V, Liu X, Chang X, Krenger PS, Plattner K, Gharailoo Z, Vogt AS, Augusto G, Zwicker M, Roongta S, Rothen DA, Josi R, Costa JJD, Sobczak JM, Nonic A, Brand LA, Nuss K, Martina B, Speiser DE, Kündig T, Jennings GT, Walton SM, Vogel M, Zeltins A, Bachmann MF. Mohsen MO, et al. Among authors: krenger ps. Allergy. 2022 Jan;77(1):243-257. doi: 10.1111/all.15080. Epub 2021 Sep 20. Allergy. 2022. PMID: 34496033 Free PMC article.
Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern.
Rothen DA, Krenger PS, Nonic A, Balke I, Vogt AS, Chang X, Manenti A, Vedovi F, Resevica G, Walton SM, Zeltins A, Montomoli E, Vogel M, Bachmann MF, Mohsen MO. Rothen DA, et al. Among authors: krenger ps. Allergy. 2022 Aug;77(8):2446-2458. doi: 10.1111/all.15311. Epub 2022 Apr 15. Allergy. 2022. PMID: 35403221 Free PMC article.